Back to Agenda
Session 3 Tracks 1 and 2: Regulatory Considerations of Novel Conjugates: Translational and Clinical Pharmacology Perspectives
Session Chair(s)
Louis St. L. O'Dea, MD
Independent Consultant, United States
Patrik Andersson, PhD
Senior Director, AstraZeneca R&D, Sweden
Session 3 Tracks 1 and 2: Regulatory Considerations of Novel Conjugates: Translational and Clinical Pharmacology Perspectives
Speaker(s)
Sydney Stern, PhD, MS
, Independent Consultant, United States
Regulatory Considerations/Principles
Representative Invited
Chief Regulatory Affairs Officer, Dyne Therapeutics, United States
Early Human/Translational Considerations[
Have an account?